Tempsens Instruments Ltd. launched its initial public offering on Aug. 20, 2024, with shares priced between ₹285 and ₹300 [1].
The offering allows the Indian medical device manufacturer to access public capital markets to scale its operations. This move comes as India seeks to expand its domestic healthcare infrastructure and medical equipment manufacturing capabilities.
The company is targeting a capital raise of approximately Rs 650 crore [3]. The IPO opened on Aug. 20, 2024, and is scheduled to close on Aug. 24, 2024 [1].
Early investor interest has been significant. By the second day of the offering, the issue was subscribed 5.94 times [3]. While some early summaries indicated the issue was subscribed 90 percent, more recent reporting suggests the higher subscription multiple [1, 3].
Market speculation regarding the listing price remains high. Livemint said there was a grey market premium of +220 [1], while MSN said there was a premium of 90 percent [2]. Based on these indicators, some forecasts place the listing price at ₹520 [1].
Grey market premiums are unofficial indicators used by traders to estimate the demand for shares before they officially trade on an exchange. A high premium typically suggests that the stock may debut at a price significantly higher than the IPO issue price.
“The company is targeting a capital raise of approximately Rs 650 crore.”
The strong subscription rate and high grey market premium indicate robust investor confidence in the Indian medical device sector. By raising Rs 650 crore, Tempsens Instruments is positioning itself to expand production capacity, which could reduce reliance on imported medical instrumentation in the region.
